RU58841 vs Finasteride for Hair Loss: What the Evidence Really Says

A few weeks ago a reader sent me a thread where someone claimed RU58841 had outperformed finasteride in a clinical trial, without side effects, and asked why nobody was talking about it. It’s a fair question. And the answer is a little more complicated than most Reddit posts let on.

Related on the Blueprint: JXL069 for Hair Loss and Finasteride Side Effects.

RU58841 is an experimental compound with a genuinely interesting mechanism. The idea behind it is appealing: block androgens right at the hair follicle, stay local, and leave your hormones alone everywhere else. Finasteride works differently. It lowers dihydrotestosterone (DHT) in your bloodstream, which means every tissue in your body feels the drop, not just your scalp. If RU58841 could match finasteride’s efficacy while skipping the systemic effects, that would matter. The problem is the gap between a compelling mechanism and a proven drug. Let’s go through what we actually know.

How each compound works

Finasteride is an inhibitor of type II 5-alpha-reductase, the enzyme that converts testosterone into DHT. Block that enzyme in the body and serum DHT drops by roughly 70 percent.^[1] Decades of randomized controlled trial data back this mechanism. Kaufman and colleagues tracked over 1,500 men for five years: the treated group gained a mean of 88 hairs (measured in a standardized one-inch target area) at two years, settling to about 38 hairs above baseline at five years. The placebo group dropped 239 hairs over the same period.^[3] Most of finasteride’s value is defensive. The follicle you keep is worth more than the one you’re trying to coax back.

RU58841 works at a different point in the same pathway. It’s a nonsteroidal androgen receptor antagonist. Instead of reducing how much DHT your body makes, it competes with DHT for the androgen receptor inside the follicle itself, blocking DHT from binding and triggering miniaturization. The design goal is local action: high concentration at the scalp, low systemic absorption, so blood levels of DHT and testosterone stay untouched.^[1] In theory, that means no downstream hormonal effects.

The evidence for finasteride (the baseline you have to beat)

Finasteride’s five-year multinational trial is the reference point for everything else.^[3] Randomized, placebo-controlled, over 1,500 men, long enough to see where the gains level off. Two-year peak: plus 88 hairs. Five-year: still 38 above baseline. Placebo at five years: minus 239 hairs. The drug didn’t just slow loss, it reversed it for years before the follicle biology eventually caught up. That’s the known quantity. Any challenger needs to beat or at least match those numbers, in humans, over real time.

It’s worth saying plainly: finasteride is FDA-approved specifically for male pattern hair loss. It has a safety database built from decades of post-market use, multiple long-term studies, and a well-characterized side-effect profile. When I say “known quantity,” I mean known in both directions, including the risks. That clarity is itself valuable.

The evidence for RU58841 (much thinner than the forums suggest)

Here is where I have to slow down and be precise. Most of the RU58841 data are in vitro (cell cultures) or animal models, specifically nude mice grafted with balding human scalp tissue.^[4] The mouse-graft model is genuinely useful for studying follicle biology, but mice are not men, and “works in a graft on a mouse” is a long way from “works in a human scalp over years.”

Two human trials under the name PSK-3841 (the pharmaceutical-grade formulation of RU58841) were registered and listed as completed in the early 2000s. Neither was published in a peer-reviewed journal.^[2] That gap matters. Companies complete trials and then don’t publish for a few reasons: the results were disappointing, the compound was abandoned for commercial reasons, or the data simply never got written up. We don’t know which applies here. What we do know is that an unpublished completed trial is not the same as a positive result.

One reported Phase II of a 5% PSK-3841 topical showed roughly a 103% increase in hair growth, compared with about 88% in an oral finasteride arm, and RU58841 didn’t lower systemic DHT or testosterone.^[1] Those numbers get cited a lot. They should be treated cautiously: this is incompletely reported data from an unpublished trial. I can’t verify the methodology, the measurement endpoints, or the patient population from what’s publicly available. The 103% figure sounds compelling. It’s also the only human hair-growth number attached to this compound, and it has never gone through peer review.

What “experimental” actually means here

RU58841 is not approved for medical use anywhere. It’s sold as a research chemical, which means purity and concentration vary between suppliers and between batches from the same supplier.^[2] There are no large-scale human trials. There is no long-term human safety profile. Nobody has tracked what happens to a man who applies it daily for five or ten years, because that study has never been done. The “no systemic effects” angle is encouraging in principle, but it’s based on the compound’s design intent and limited early data, not on long-term pharmacokinetic monitoring in large cohorts.

Think of it this way: RU58841 is like a prototype car that performed impressively in early test laps. The engineering concept is sound. The first runs looked fast. But the company quietly shelved the project before putting it through crash testing, and now some people are driving it on public roads anyway, because the prototype is easy to buy online and the concept is compelling. The mechanism isn’t wrong. The crash testing just never happened.

That’s not a reason to say the compound definitely doesn’t work. It’s a reason to be honest about what we know and what we don’t.

The comparison table

Why the local-action idea is appealing but not enough

I want to be fair to the RU58841 argument, because it isn’t stupid. The side effects most commonly associated with finasteride, such as changes in libido or sexual function, are thought to be related to the drop in systemic DHT and possibly changes in neurosteroid levels. If you could achieve equivalent follicle-level androgen blockade without touching blood hormone levels, you’d sidestep that mechanism entirely. That’s a real and worth-taking-seriously hypothesis.^[2]

But a hypothesis, even a good one, is not a proven drug. The appeal of a mechanism does not substitute for randomized trial data, peer-reviewed outcomes, or long-term safety monitoring. The people running RU58841 communities online are, by and large, doing informal self-experimentation on a compound where the only large-scale human testing was done, completed, and then quietly not published. That’s the bit I find genuinely strange. When a pharmaceutical company completes a trial and doesn’t publish, that’s a signal worth paying attention to.

What I’d actually recommend

If you’re researching your options for male pattern hair loss, finasteride is still the most evidence-backed oral intervention available. It’s not perfect. The side-effect conversation is real and shouldn’t be dismissed. Some men don’t tolerate it. But it’s a compound that has been put through rigorous testing, scrutinized in peer review, and followed in patients over years. You know, roughly, what you’re getting.

RU58841 might eventually earn a proper evidence base. But “might eventually” and “published human RCT data” are separated by a gap that matters enormously when you’re deciding what to put on your body long-term. If a company ran the trials, had promising data, and chose to publish: you’d be reading those papers right now. The fact that you’re reading forum posts and secondhand reports instead should factor into your thinking.

I cover the broader landscape of androgenetic alopecia treatments, including what the mechanism research actually tells us, at philippeb.pro. The details matter more than the headlines.

The bottom line

RU58841 has an interesting mechanism. The local-androgen-blockade idea is worth taking seriously as a concept. The evidence base, however, is almost entirely preclinical, with two human trials that were run and never published, and one incompletely reported efficacy number that’s circulated without peer review for two decades. Finasteride has 70-percent serum DHT suppression, a five-year randomized controlled trial showing real numbers (plus 88 at two years, placebo minus 239 at five), and a known safety profile built from decades of use.

That gap is not a small one. It’s the difference between a compound that’s been tested, scrutinized, and followed for years, and a research chemical sold online with variable purity and no long-term human data. Both may have a role in the future of hair-loss treatment. Right now, only one of them has earned the evidence to say so.